Download PDF

Neurotherapeutics

, Volume 4, Issue 4, pp 654–660 | Cite as

Immunosuppressive agents in multiple sclerosis

  • Oliver Neuhaus
  • Bernd C. Kieseier
  • Hans-Peter Hartung
Review Article

Summary

Immunosuppressive agents have been used in multiple sclerosis (MS) for decades. The approval of several immunomodulatory agents against MS beginning in the 1990s, whose putative mechanisms of action appeared “more MS-specific,” curtailed the importance of immunosuppressants, which made them treatment options of second choice. However, with the recent approval of mitoxantrone for treatment of patients with active forms of relapsing-remitting or secondary progressive MS and with a number of oral immunosuppressive agents being assessed in phase II and III clinical trials, a “renaissance” of this type of agents is currently occurring. This review provides an outline of the most important clinical studies and discusses relevant side effects of the major immunosuppressants (i.e., mitoxantrone, azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, cladribine, and sirolimus/temsirolimus). The current knowledge of the putative mechanisms of action of these compounds is discussed.

Key Words

Multiple sclerosis immunosuppressive agents mitoxantrone azathioprine cyclophosphamide methotrexate mycophenolate mofetil cladribine (tem)sirolimus 
Download to read the full article text

References

  1. 1.
    The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655–661.Google Scholar
  2. 2.
    Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285–294.CrossRefPubMedGoogle Scholar
  3. 3.
    PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–1504.CrossRefGoogle Scholar
  4. 4.
    Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268–1276.PubMedGoogle Scholar
  5. 5.
    Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol 2003;23: 133–145.CrossRefPubMedGoogle Scholar
  6. 6.
    Smith IE. Mitoxantrone (Novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 1983;10: 103–115.CrossRefPubMedGoogle Scholar
  7. 7.
    Shenkenberg TD, von Hoff D. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 1986; 105:67–81.PubMedGoogle Scholar
  8. 8.
    Ridge SC, Sloboda AE, McReynolds RA, Levine S, Oronsky AL, Kerwar SS. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 1985;35:35–42.CrossRefPubMedGoogle Scholar
  9. 9.
    Levine S, Saltzman A. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol 1986;13:175–181.CrossRefPubMedGoogle Scholar
  10. 10.
    Lublin FD, Lasvasa M, Viti C, Knobler RL. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987;45:122–128.CrossRefPubMedGoogle Scholar
  11. 11.
    Edan G, Morrissey SP, Hartung HP. Use of mitoxantrone to treat multiple sclerosis. In: Cohen JA, Rudick RA, eds. Multiple sclerosis therapeutics. London, New York: Martin Dunitz, 2003:403–426.Google Scholar
  12. 12.
    Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112–118.CrossRefPubMedGoogle Scholar
  13. 13.
    Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153–159.CrossRefPubMedGoogle Scholar
  14. 14.
    Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.PubMedGoogle Scholar
  15. 15.
    Van de Wyngaert FA, Beguin C, D’Hooge MB, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 2001;101:210–216.PubMedGoogle Scholar
  16. 16.
    Hartung HP, Gonsette R, König N, et al. A placebo-controlled, double-blind, randomised, multicentre trial of mitoxantrone in progressive multiple sclerosis. Lancet 2002;360:2018–2025.CrossRefPubMedGoogle Scholar
  17. 17.
    Krapf H, Morrissey SP, Zenker O, et al. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005;65:690–695.CrossRefPubMedGoogle Scholar
  18. 18.
    Jain KK. Evaluation of mitoxantrone for the treatment of multiple sclerosis. Exp Opin Invest Drugs 2000;9: 1139–1149.CrossRefGoogle Scholar
  19. 19.
    Stiive O, Cree BC, von Büdingen HC, et al. Approved and future pharmacotherapy for multiple sclerosis. Neurologist 2002;8:290–301.CrossRefGoogle Scholar
  20. 20.
    Neuhaus O, Kieseier BC, Hartung HP. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther 2006;109:198–209.CrossRefPubMedGoogle Scholar
  21. 21.
    Fidler JM, de Joy SQ, Gibbons JJ. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986;137:727–732.PubMedGoogle Scholar
  22. 22.
    Fidler JM, de Joy SQ, Smith FR, Gibbons JJ. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone treated mice. J Immunol 1986;136: 2747–2754.PubMedGoogle Scholar
  23. 23.
    Mauch E, Komhuber HH, Krapf H, Fetzer U, Laufen H. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992;242:96–102.CrossRefPubMedGoogle Scholar
  24. 24.
    Gbadamosi J, Buhmann C, Tessmer W, Moench A, Haag F, Heesen C. Effects of mitoxantrone on multiple sclerosis patients’ lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur Neurol 2003;49:137–141.CrossRefPubMedGoogle Scholar
  25. 25.
    Bellosillo B, Colomer D, Pons G, Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 1998;100:142–146.CrossRefPubMedGoogle Scholar
  26. 26.
    Neuhaus O, Wiendl H, Kieseier BC, et al. Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005;168:128–137.CrossRefPubMedGoogle Scholar
  27. 27.
    Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005;139:152–158.CrossRefPubMedGoogle Scholar
  28. 28.
    Khoury SJ, Bharanidharan P, Bourcier K, Cook SL, Stazzone L, Weiner HL. Immunologic effects of mitoxantrone therapy in patients with multiple sclerosis. Neurology 2002;58 (supplement 3): A245-A246 (abstract).Google Scholar
  29. 29.
    Kopadze T, Dehmel T, Hartung HP, Stuve O, Kieseier BC. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol 2007;63:1572–1578.CrossRefGoogle Scholar
  30. 30.
    Edan G, Brochet B, Clanet M, et al. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4 year mean follow-up study. Neurology 2004;62(supplement 5):A493 (abstract).Google Scholar
  31. 31.
    Rivera V, Al-Sabbagh A, Bennett R, et al. Ongoing evaluation of the safety and tolerability of mitoxantrone in worsening multiple sclerosis: the RENEW study. Neurology 2007;68 (supplement 1): A275 (abstract).Google Scholar
  32. 32.
    De Castro S, Cartoni D, Millefiorini E, et al. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing-remitting multiple sclerosis. J Clin Pharmacol 1995;35:627–632.PubMedGoogle Scholar
  33. 33.
    Gonsette RE. Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler 1996;l:329–332.Google Scholar
  34. 34.
    Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909–913.CrossRefPubMedGoogle Scholar
  35. 35.
    Edan G, Brochet B, Clanet M, et al. Safety profile of mitoxantrone in a cohort of 800 multiple sclerosis patients. Mult Scler 2001;7 (supplement 1):S14 (abstract).Google Scholar
  36. 36.
    Mauch E, Eisenman S, Hahn A, Zenker O, Rubin A, Ghalie R. Mitoxantrone in the treatment of patients with multiple sclerosis: a large single center experience. Mult Scler 1999;5(supplement 1): P366 (abstract).Google Scholar
  37. 37.
    Herman EH, Zhang J, Rifai N, et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 2001;48: 297–304.CrossRefPubMedGoogle Scholar
  38. 38.
    Bemitsas E, Wei W, Mikol DD. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann Neurol 2006;59:206–209.CrossRefGoogle Scholar
  39. 39.
    Weilbach FX, Chan A, Toyka KV, Gold R. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol 2004;135:49–55.CrossRefPubMedGoogle Scholar
  40. 40.
    Gonsette RE. Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. J Neurol Sci 2004; 223:81–86.CrossRefPubMedGoogle Scholar
  41. 41.
    Ghalie RG, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002;8:441–445.CrossRefPubMedGoogle Scholar
  42. 42.
    Vicari AM, Ciceri F, Folli F, et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998;12:441–442.CrossRefPubMedGoogle Scholar
  43. 43.
    Brassat D, Recher C, Waubant E, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002;59:954–955.PubMedGoogle Scholar
  44. 44.
    Heesen C, Bruegmann M, Gbadamosi J, Koch E, Monch A, Buhmann C. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult Scler 2003;9: 213–214.CrossRefPubMedGoogle Scholar
  45. 45.
    Jaster JH, Niell HB, Dohan FCJ, Smith TW. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2003;60:1399–1400.PubMedGoogle Scholar
  46. 46.
    Cattaneo C, Almici C, Borlenghi E, Motta M, Rossi G. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia 2003;17:985–986.CrossRefPubMedGoogle Scholar
  47. 47.
    Mogenet I, Simiand-Erdociain E, Canonge JM, Ris J. Acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis. Ann Pharmacother 2003;37:747–748.CrossRefPubMedGoogle Scholar
  48. 48.
    Voltz R, Starck M, Zingler V, Strupp M, Kolb HJ. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler 2004;10:472–474.CrossRefPubMedGoogle Scholar
  49. 49.
    Arruda WO, Montu MB, de Oliveira MdS, Ramina R. Acute myeloid leukaemia induced by mitoxantrone: case report. Arq Neuropsiquiatr 2005;63:327–329.PubMedGoogle Scholar
  50. 50.
    Nollet S, Berger E, Deconinck E, Baldauf E, Rumbach L. Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone. Rev Neurol (Paris) 2006;162:195–199.Google Scholar
  51. 51.
    Ledda A, Caocci G, Spinicci G, Cocco E, Mamusa E, Nasa GL. Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. Leukemia 2006;20: 2217–2218.CrossRefPubMedGoogle Scholar
  52. 52.
    Cartwright MS, Jeffery DR, Lewis ZT, Koty PP, Stewart WT, Molnar I. Mitoxantrone for multiple sclerosis causing acute lymphoblastic leukemia. Neurology 2007;68:1630–1631.CrossRefPubMedGoogle Scholar
  53. 53.
    Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol 2000;20:108–125.PubMedGoogle Scholar
  54. 54.
    British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988: 179–183.Google Scholar
  55. 55.
    Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051–1055.CrossRefPubMedGoogle Scholar
  56. 56.
    Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet 1997;350:261.CrossRefPubMedGoogle Scholar
  57. 57.
    Lhermitte F, Marteau R, Roullet E. Not so benign long-term immunosuppression in multiple sclerosis. Lancet 1984;1(8371): 276–277.CrossRefPubMedGoogle Scholar
  58. 58.
    Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996;46:1607–1612.PubMedGoogle Scholar
  59. 59.
    Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis. New aspects and practical application. J Neurol 2004;251:1329–1339.CrossRefGoogle Scholar
  60. 60.
    The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337:441–446.Google Scholar
  61. 61.
    Hauser S, Dawson D, Lehrich J, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173–180.CrossRefPubMedGoogle Scholar
  62. 62.
    Goodkin DE, Plencner S, Palmer-Saxerud J, Teetzen M, Hertsgaard D. Cyclophosphamide in chronic progressive multiple sclerosis: maintenance vs nonmaintenance therapy. Arch Neurol 1987; 44:823–827.PubMedGoogle Scholar
  63. 63.
    Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993;43:910–918.PubMedGoogle Scholar
  64. 64.
    La Mantia L, Milanese C, D’Amico R, Mascoli N, Weinstock-Guttman B. Cyclophosphamide in progressive multiple sclerosis: systematic review and meta-analysis of randomized trials. In: Columbus F, ed. Treatment and management of multiple sclerosis. Hauppauge, NY: Nova Science Publishers; 2005:33–48.Google Scholar
  65. 65.
    Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002;8:142–154.CrossRefPubMedGoogle Scholar
  66. 66.
    Goodkin DE, Rudick RA, VanderBrug-Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic preogressive multiple sclerosis. Ann Neurol 1995;37:30–40.CrossRefPubMedGoogle Scholar
  67. 67.
    Ahrens N, Salama A, Haas J. Mycophenolate mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001;248:713–714.CrossRefPubMedGoogle Scholar
  68. 68.
    Frohman EM, Brannon K, Racke MK, et al. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004;27:80–83.CrossRefPubMedGoogle Scholar
  69. 69.
    Vermersch P, Waucquier N, Michelin E, et al. Combination of IFNbeta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. Eur J Neurol 2007;14:85–89.CrossRefPubMedGoogle Scholar
  70. 70.
    Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992;340:952–956.CrossRefPubMedGoogle Scholar
  71. 71.
    Sipe JC. Cladribine for multiple sclerosis: review and current status. Exp Rev Neurotherapeutics 2005;5:721–727.CrossRefGoogle Scholar
  72. 72.
    Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9–13.CrossRefPubMedGoogle Scholar
  73. 73.
    Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996;93:1716–1720.CrossRefPubMedGoogle Scholar
  74. 74.
    Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999;111:35–44.CrossRefPubMedGoogle Scholar
  75. 75.
    Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000;54:1145–1155.PubMedGoogle Scholar
  76. 76.
    Brousil JA, Roberts RJ, Schiein AL. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Ann Pharmacother 2006;40:1814–1821.CrossRefPubMedGoogle Scholar
  77. 77.
    Kappos L, Barkhof F, Desmet A. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomised, controlled clinical trial. J Neurol 2005;252(supplement 2): S46 (abstract).Google Scholar
  78. 78.
    Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Roc 2003;35(supplement 3): 7S-14S.CrossRefGoogle Scholar
  79. 79.
    Weinstock-Guttman B, Kinkel RP, Cohen JA, et al. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. Neurologist 1997;3:178–185.CrossRefGoogle Scholar
  80. 80.
    Confavreux C, Vukusic S. Non-specific immunosuppressants in the treatment of multiple sclerosis. Clin Neurol Neurosurg 2004; 106:263–269.CrossRefPubMedGoogle Scholar

Copyright information

© Springer New York 2007

Authors and Affiliations

  • Oliver Neuhaus
    • 1
  • Bernd C. Kieseier
    • 2
  • Hans-Peter Hartung
    • 2
  1. 1.Department of NeurologyKliniken Landkreis Sigmaringen GmbHSigmaringenGermany
  2. 2.Department of NeurologyHeinrich Heine UniversityDüsseldorfGermany

Personalised recommendations